11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
83 citations
,
June 2018 in “Frontiers in immunology” Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
10 citations
,
May 2019 in “Seminars in Cell & Developmental Biology” Understanding and manipulating epigenetic changes can potentially lead to human organ regeneration therapies, but more research is needed to improve these methods and minimize risks.
January 2024 in “Advances in Dermatology and Allergology” New treatments offer hope for better managing hidradenitis suppurativa.
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The summit aimed to speed up finding treatments for alopecia areata.
63 citations
,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
October 2025 in “Clinical Cosmetic and Investigational Dermatology” Targeting specific cell interactions may help treat skin fibrosis.
148 citations
,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
14 citations
,
January 2020 in “Advances in Dermatology and Allergology” Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.
January 2016 in “Springer eBooks” Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.
60 citations
,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
102 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Restoring hair bulb immune privilege is crucial for managing alopecia areata.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
22 citations
,
June 2012 in “PLOS ONE” Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
3 citations
,
June 2022 in “Dermatology and therapy” A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.